Hyderabad News Desk

DelveInsight’s, “Psoriatic Arthritis Pipeline Insight 2024” report provides comprehensive insights about 50+ Psoriatic Arthritis companies and 50+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the Psoriatic Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriatic Arthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Psoriatic Arthritis Pipeline Report

• DelveInsight’s Psoriatic Arthritis pipeline report depicts a robust space with 50+ Psoriatic Arthritis companies working to develop 50+ pipeline therapies for Psoriatic Arthritis treatment.
• The leading companies working in the Psoriatic Arthritis Market include Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others.
• Promising Psoriatic Arthritis Pipeline Therapies in the various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.
• September 2023: ACELYRIN Inc. announced a study of phase 2 & 3 clinical trials for Izokibep. Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
• September 2023: Novartis Pharmaceuticals announced a study of phase 3 clinical trials for Secukinumab and Ustekinumab. The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment.

Request a sample and discover the recent advances in Psoriatic Arthritis Treatment Drugs @ Psoriatic Arthritis Pipeline Report

In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Psoriatic Arthritis Overview

Psoriatic Arthritis is a chronic inflammatory disease of the joints that can be associated with the psoriasis. It can affect both peripheral joints and axial skeleton causing pain, stiffness, swelling and joint destruction. This joint pathology develops gradually and cause more nuisance than disabling. Psoriatic arthritis is considered as seronegative spondyloarthropathies.

Find out more about Psoriatic Arthritis Therapeutics Assessment @ Psoriatic Arthritis Preclinical and Discovery Stage Products

Psoriatic Arthritis Emerging Drugs Profile

• ABT-494: AbbVie
• Risankizumab: Abbvie

Psoriatic Arthritis Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Psoriatic Arthritis therapies. The companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Registered include, Abbvie.

Learn more about the emerging Psoriatic Arthritis Pipeline Therapies @ Psoriatic Arthritis Clinical Trials Assessment

Scope of the Psoriatic Arthritis Pipeline Report

• Coverage- Global
• Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriatic ArthritisTherapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Psoriatic Arthritis Companies- Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cedilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and others.
• Psoriatic Arthritis Pipeline Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, Methotrexate (MTX), and others.

Dive deep into rich insights for new drugs for Psoriatic Arthritis Treatment, Visit @ Psoriatic Arthritis Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Psoriatic Arthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriatic Arthritis– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Psoriatic Arthritis Collaboration Deals
9. Late Stage Products (Registered/Launch)
10. MYL-1401A: Mylan
11. Drug profiles in the detailed report…..
12. Late Stage Products (Registered)
13. ABT-494: AbbVie
14. Drug profiles in the detailed report…..
15. Late Stage Products (Preregistration)
16. Tildrakizumab: Sun Pharma Global
17. Drug profiles in the detailed report…..
18. Late Stage Products (Phase III)
19. Filgotinib: Gilead Sciences
20. Drug profiles in the detailed report…..
21. Mid Stage Products (Phase II)
22. PF-06700841: Pfizer
23. Drug profiles in the detailed report…..
24. Early Stage Products (Phase I)
25. BAT2506: Bio-Thera Solutions
26. Drug profiles in the detailed report…..
27. IND Stage Products
28. KPG-612: Kangpu Biopharmaceuticals
29. Drug profiles in the detailed report…..
30. Preclinical Stage Products
31. ALPN 101: Alpine Immune Sciences
32. Drug profiles in the detailed report…..
33. Discovery Stage Products
34. DNX 514: DNX Biopharmaceuticals
35. Inactive Products
36. Psoriatic Arthritis Key Companies
37. Psoriatic Arthritis Key Products
38. Psoriatic Arthritis- Unmet Needs
39. Psoriatic Arthritis- Market Drivers and Barriers
40. Psoriatic Arthritis- Future Perspectives and Conclusion
41. Psoriatic Arthritis Analyst Views
42. Psoriatic Arthritis Key Companies
43. Appendix

For further information on the Psoriatic Arthritis Pipeline therapeutics, reach out to Psoriatic Arthritis Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services